What is China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (600062.SS) StockRank?

MoatMap's StockRank for China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS) is 88/100, with a Strong Buy signal. This is a composite score combining Quality (69), Value (57), and Momentum (51) factor ranks across MoatMap's 19,000+ stock universe.

Does China Resources Double-Crane Pharmaceutical Co.,Ltd. have an economic moat?

China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS) has a Quality factor score of 69/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is China Resources Double-Crane Pharmaceutical Co.,Ltd. a buy, hold, or sell?

MoatMap's current signal for China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS) is Strong Buy, based on a StockRank of 88/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is China Resources Double-Crane Pharmaceutical Co.,Ltd. in?

China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

600062.SS

STRONG BUYREMOVE

China Resources Double-Crane Pharmaceutical Co.,Ltd. · Healthcare · China · $2.6B · Avg Vol: $13M/d

StockRank

P/E (TTM)

10.8x

ROE

13.5%

D/E

0.1x

Dividend %

2.8%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

China Resources Double-Crane is a domestic-focused Chinese pharmaceutical firm specializing in generic drugs and basic infusions, lacking the pricing power and regulatory moats of high-end CDMOs.

COMPANY DESCRIPTION

China Resources Double-Crane Pharmaceutical Co.,Ltd. is a leading pharmaceutical manufacturer specializing in large-volume infusions, cardiovascular drugs, and endocrine treatments. As a key subsidiary of China Resources Group, the company benefits from extensive distribution synergies and strong brand recognition in domestic hospitals. Its high-volume, low-cost manufacturing capabilities in essential medicines provide a highly defensive revenue stream.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	1.4B	1.7B	1.7B	1.6B	4.6%
EPS	0.17	0.24	0.23	0.24	11.9%
Shares	1.0B	1.0B	1.0B	1.0B	-0.4%
Debt	39M	43M	178M	177M	65.2%
Equity	1.6B	1.8B	1.5B	1.7B	3.3%
Op CF	209M	275M	270M	220M	1.7%
Inv CF	88M	-116M	145M	-155M	—
Fin CF	-191M	-72M	-471M	-203M	—

PRICE (1M)-6.5%

SMA 50SMA 200

$2.48

RSI (14)

48.3

52W High

$3.26

From 52W High

0.8%

SCORE BREAKDOWN

Quality

ROIC

13.9%82.9

ROE

13.5%79.7

GP/Assets

36.2%75.0

Op. Margin

19.9%82.1

FCF/Assets

0.8%53.3

Piotroski

—55.8

Int. Cover

50.0x91.4

D/E Ratio

0.13x61.7

Current Ratio

2.67x48.1

Value

P/E (TTM)

10.8x86.3

EV/EBITDA

7.1x51.8

P/FCF

911.9x8.9

P/B

1.4x67.5

P/S

1.6x73.3

Div Yield

2.8%65.4

Momentum

52W High %

76%67.6

RS 6M

-19%56.8

SMA 50/200

0.95x48.4

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+18%32.9

Q Growth

-4%36.5

FUNDAMENTALS

Market Cap

$2.6B

P/E (Forward)

9.1x

Gross Margin

57.2%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 600062.SS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
600062.SS	China Resources Double-Crane Pharmaceutical Co.,Ltd.(you)	$2.6B	88	STRONG BUY
600867.SS	Tonghua Dongbao Pharmaceutical Co., Ltd.	$2.4B	90	STRONG BUY
000739.SZ	Apeloa Pharmaceutical Co.,Ltd	$2.8B	91	STRONG BUY
600535.SS	Tasly Pharmaceutical Group Co., Ltd	$3.1B	86	STRONG BUY
600380.SS	Joincare Pharmaceutical Group Industry Co.,Ltd.	$2.8B	93	STRONG BUY
2096.HK	Simcere Pharmaceutical Group Limited	$3.3B	91	STRONG BUY
605507.SS	Guobang Pharma Ltd.	$1.8B	88	STRONG BUY
600750.SS	China Resources Jiangzhong Pharmaceutical Co.,Ltd	$2.4B	94	STRONG BUY
600216.SS	Zhejiang Medicine Co., Ltd.	$1.8B	90	STRONG BUY
600420.SS	Shanghai Shyndec Pharmaceutical Co., Ltd.	$1.8B	85	STRONG BUY

Peer medians: ROE 4.7% · P/E 27.9x · Gross margin 53.0%

China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS) — Stock Score Summary

China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS) has a MoatMap StockRank of 88/100 based on Quality (69/100), Value (57/100), and Momentum (51/100) factor scores. The current signal is STRONG BUY. China Resources Double-Crane is a domestic-focused Chinese pharmaceutical firm specializing in generic drugs and basic infusions, lacking the pricing power and regulatory moats of high-end CDMOs.

Key Financial Metrics

Price	$2.48
Market Cap	$2.6B
P/E (TTM)	10.83
P/E (Forward)	9.15
Price/Book	1.45
Return on Equity	13.5%
Return on Invested Capital	13.9%
Debt/Equity	12.98
Gross Margin	57.2%
Operating Margin	19.9%
Revenue Growth	-8.8%
Dividend Yield	2.8%
Free Cash Flow	$3M

China Resources Double-Crane Pharmaceutical Co.,Ltd. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is China Resources Double-Crane Pharmaceutical Co.,Ltd.’s (600062.SS) StockRank?: MoatMap’s StockRank for China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS) is 88/100, with a Strong Buy signal. It is a composite of Quality (69), Value (57), and Momentum (51) factor ranks across MoatMap’s 19,000+ stock universe.
Does China Resources Double-Crane Pharmaceutical Co.,Ltd. have an economic moat?: China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS) has a Quality factor score of 69/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is China Resources Double-Crane Pharmaceutical Co.,Ltd. a buy, hold, or sell?: MoatMap’s current signal for China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS) is Strong Buy, based on a StockRank of 88/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is China Resources Double-Crane Pharmaceutical Co.,Ltd. in?: China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).